NEW YORK (GenomeWeb) – Rosetta Genomics today announced a nearly 800 percent jump in third quarter revenues from continuing operations as the company benefitted from the sale of products from PersonalizeDx, a molecular diagnostics firm acquired in April.

For the three-month period ended Sept. 30, Rosetta's revenues from continuing operations increased to $2.4 million from $273,000 in the same period last year.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The Atlantic reports that genetic counselors are coping with an influx of patients seeking advice on their direct-to-consumer genetic test results.

A small study finds differences between three genomic prostate cancer tests, Medscape reports.

In Nature this week: shared genetic architecture for asthma and allergic diseases, and more.

A survey of Canadians finds them to be divided on genetically modified food, the Ottawa Citizen reports.